Regulus Therapeutics (RGLS) announces Simos Simeonidis resigns from board

Regulus Therapeutics Inc. (Nasdaq: RGLS),announced that Simos Simeonidis, Ph.D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment as co-Chief Executive Officer and co-Chief Investment Officer at Ally Bridge Group. His resignation was effective December 6, 2022.

"On behalf of the Board and the whole team at Regulus, I would like to thank Simos for his impactful leadership during his tenure at Regulus," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus. "Since joining the Board, Simos, with his expertise in investment management and biomedical research, has provided the team with invaluable insights that have helped Regulus achieve milestones and position the company for long-term success."

"Simos has been a valuable member of our team and we have appreciated his experience, dedication and thoughtful guidance as a Board member," said Jay Hagan, President and Chief Executive Officer of Regulus Therapeutics. "We appreciate his service and commitment to Regulus and wish him all the best in his future endeavors."

"It has been my pleasure to work with the Regulus management team in advancing the clinical development of RGLS8429," said Dr. Simeonidis. "I look forward to seeing the company continue its progress and deliver on novel targeted microRNA-based therapies for the treatment of ADPKD."

You May Also Be Interested In

• Patrick Bombach resigns from Mobileye board amid Intel departure
• Keurig Dr Pepper names Cardinal Health CFO to its board
• Everspin Technologies adds semiconductor veteran to its board